After confirming that the production of IL-18 by CAR-T cells enhanced the antitumoral effect against a Burkitt lymphoma model, we wanted to validate the use of iTRUCK19.18 cells in a clinically relevant setting. The gene discussed is IL18; the disease is Burkitt lymphoma.